mRNA therapeutics

What the product actually is

An mRNA product supplies a coding sequence that the recipient's own cells translate into protein for a limited period. Two things follow that shape everything downstream. The active substance is not the administered material but the protein the body makes from it, so exposure is measured indirectly. And the message cannot enter a cell unaided, so the product is always a combination of the sequence and a delivery vehicle, most commonly a lipid nanoparticle.^[S5] Nonclinical work in this area is largely work on that combination rather than on the sequence alone.

Is this a gene therapy? The classification question comes first

The FDA's cell and gene therapy centre defines human gene therapy as seeking to modify or manipulate the expression of a gene, or to alter the biological properties of living cells, for therapeutic use.^[S4] Separately, the FDA has stated of the first approved COVID-19 vaccine that its mRNA is not incorporated into, and does not alter, an individual's genetic material.^[S1] Read together, these support treating a prophylactic mRNA vaccine of that type as distinct from a gene therapy product. Two cautions apply. The FDA does not state this equivalence in a single sentence; it is a reading of two documents. And it is a general principle rather than a rule covering every mRNA design, since a message encoding a gene-editing payload raises a different question. Classification determines which centre reviews the application and which framework the nonclinical package is built against, so it is a question to settle with the agency at a pre-IND meeting rather than to assume.

Approved products and products in development

Comirnaty

Comirnaty was the first COVID-19 vaccine the FDA approved, having previously been available under the Pfizer-BioNTech name.^[S1] It uses a lipid nanoparticle to deliver the message. For a developer the useful point is that this establishes a reviewed precedent for the platform, which is a different situation from bringing an unprecedented delivery vehicle to the agency.

Spikevax

Spikevax is a second approved mRNA vaccine of the same general construction, with an indication defined by age and underlying condition.^[S2] Two approved products using the same delivery approach means the questions a new sponsor will be asked are informed by two prior reviews, not one.

Individualized cancer vaccines (investigational)

These encode neoantigens identified from an individual patient's tumour and are investigational. They raise a nonclinical problem that has no counterpart in a conventional product: the sequence differs for every patient, so the material used in animal studies cannot be the material given to any patient. What is characterized nonclinically is the platform, meaning the delivery vehicle, the manufacturing process and the general behaviour of the construct type, rather than the specific product. How much platform data supports an individualized product is a question to raise with the agency early.

The problems specific to this modality

The delivery vehicle is part of the product

Naked mRNA is taken up poorly and degraded quickly, so a vehicle is required. Lipid nanoparticles have entered clinical use for this purpose.^[S5] The consequence for nonclinical work is that the vehicle has its own distribution, its own toxicity and its own immunological behaviour, none of which is a property of the message. A change to the lipid composition is a change to the product, and data generated with one formulation does not automatically support another.

Expression is the exposure measure

Because the active substance is produced in the body, the pharmacokinetic question is not plasma concentration of the administered material but how much protein was made, where, and for how long. Two products delivering the same sequence can differ substantially in all three. This has to be measured in tissue, and the assay for the expressed protein is a piece of method development that belongs on the critical path rather than being assumed available.

Immune stimulation cuts both ways

Nucleic acids are recognized by innate immune sensors, and the literature describes this inherent immunogenicity as a double-edged sword: an adjuvant effect that is useful in a vaccine becomes a detrimental inflammatory response in other settings.^[S7] What nonclinical work does about this is characterize the response, meaning which cytokines rise, at what dose, and how quickly they return to baseline. Sponsors commonly use these measurements to describe the risk; this article makes no claim that they predict clinical outcomes, and no source was found supporting such a claim.

The nonclinical work

Biodistribution

There is no dedicated nonclinical guidance for this modality

This research pass located no FDA guidance written specifically for the nonclinical evaluation of mRNA and lipid nanoparticle products. The framework most often cited, on preclinical safety evaluation of biotechnology-derived pharmaceuticals, was written for proteins and antibodies and combined with its addendum in 2011.^[S3] It does not address a product whose active substance is synthesized by the recipient or one whose vehicle is a lipid particle with its own distribution. The practical consequence is that the applicable framework for a specific product is agreed with the agency rather than read off a document. Sponsors should raise it at a pre-IND meeting and should expect the answer to depend on how the product is classified.

Three distributions have to be tracked separately: where the lipid particle goes, where the message goes, and where the protein appears. They are not the same, and measuring one does not report the other. Lipid components can persist in tissue after the message has been degraded, which is a distinct question from expression and is assessed with its own analytical method.

Expression and pharmacology

The chain to establish is that the message reached cells, that protein was made, and that the protein did what it was supposed to do. A break at any link produces the same negative result, so measuring only the last one leaves the cause undiagnosed. Where the expressed protein is an antigen, the readout is the immune response it raised; where it is a replacement protein, the readout is the function that protein performs.

Model selection

One constraint dominates model selection here. Innate immune sensing of nucleic acids differs between species, so the inflammatory response measured in a mouse is not the response a person would have.^[S7] Human cell systems address that specific question and are used alongside animal studies rather than instead of them, since a cell system cannot report distribution. Neither arrangement resolves the difference; what they do is make it visible.

Safety assessment

Cytokine measurement, liver function and histopathology, and injection site assessment are the usual areas. Attribution matters here more than usual: a finding may come from the message, from the expressed protein, or from the lipid vehicle, and separating them generally requires running the vehicle alone as a control arm. That control is easy to omit at the planning stage and impossible to add afterwards.

Repeat dosing raises a question the vaccines did not have to answer

Lipid nanoparticles commonly include a polyethylene glycol lipid, and the literature discusses anti-PEG antibody production and complement activation as consequences of that.^[S6] For a product given once or twice this may not surface. For a chronic product given repeatedly it can change exposure over the course of treatment and can produce reactions on later doses that the first dose did not. A nonclinical repeat-dose study in this area should therefore be designed to look for it: anti-PEG antibody measurement and complement assessment as endpoints, with enough doses that a response has time to develop.

What to establish with the laboratory

Four things are worth establishing before award. Whether the laboratory can quantify the lipid components, the message and the expressed protein as three separate measurements, and which of those it would need to develop. Whether its study designs include a vehicle-only control arm as standard. Whether it can measure anti-PEG antibodies and complement activation if the product will be dosed repeatedly.^[S6] And what human cell systems it has for innate immune stimulation, given the species difference in nucleic acid sensing.^[S7]

About this article

This is an independent editorial article for people who commission nonclinical work in the United States. Approvals and regulatory definitions are taken from FDA sources as published and are recorded as facts; this site does not discuss the efficacy of any product or compare products. Where a regulatory position is inferred from more than one document, that is stated in the text. Regulatory classification for a specific product should be confirmed with the agency. It does not recommend any laboratory. Last reviewed: September 3, 2026.

References

1. FDA News Release — FDA Approves First COVID-19 Vaccine. https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine (accessed 2026-09-03)
2. FDA — SPIKEVAX biologics product page（CBER）. https://www.fda.gov/vaccines-blood-biologics/spikevax (accessed 2026-09-03)
3. FDA — ICH S6(R1) Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s6-r1-addendum-preclinical-safety-evaluation-biotechnology-derived-pharmaceuticals (accessed 2026-09-03)
4. FDA — What is Gene Therapy?（CBER, Cellular & Gene Therapy Products）. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/what-gene-therapy (accessed 2026-09-03)
5. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nature Reviews Materials, 2021. https://pubmed.ncbi.nlm.nih.gov/ (accessed 2026-09-03)
6. Gao P. PEGylated lipids in lipid nanoparticle delivery dynamics and therapeutic innovation. Beilstein Journal of Nanotechnology. https://pubmed.ncbi.nlm.nih.gov/ (accessed 2026-09-03)
7. Hu R, Dou Y, Li C. Decoding Undesirable Inflammatory Responses of Nucleic Acid. https://pubmed.ncbi.nlm.nih.gov/ (accessed 2026-09-03)